• Provention Bio tees up for $50M IPO fiercebiotech
    May 16, 2018
    Provention Bio has filed to raise up to $50 million in its Nasdaq IPO, which will bankroll several clinical programs, including a pair of inflammatory bowel disease assets it picked up from Janssen last fall.
PharmaSources Customer Service